Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29802982 | 1.00 | MAPT (0.65) | MAPTALDH1A1LMNASIRT6KDM4E | |
| SCHEMBL17411227 | 0.91 | ALDH1A1 (0.59) | MAPTALDH1A1LMNASIRT6KDM4E | |
| SCHEMBL15863324 | 0.91 | ALDH1A1 (0.65) | MAPTALDH1A1LMNASIRT6KDM4E | |
| SCHEMBL310101 | 0.91 | GPR119 (0.59) | MAPTALDH1A1LMNASIRT6 | |
| SCHEMBL517794 | 0.90 | ALDH1A1 (0.55) | MAPTALDH1A1LMNASIRT6ALK | |
| SCHEMBL310364 | 0.90 | SIRT6 (0.55) | MAPTALDH1A1LMNASIRT6KDM4E | |
| SCHEMBL25370804 | 0.89 | SIRT6 (0.56) | MAPTALDH1A1LMNASIRT6KDM4E | |
| SCHEMBL22954613 | 0.89 | ALDH1A1 (0.54) | MAPTALDH1A1LMNASIRT6KDM4E | |
| SCHEMBL28795348 | 0.89 | ALDH1A1 (0.53) | MAPTALDH1A1LMNASIRT6KDM4E | |
| SCHEMBL16270620 | 0.88 | MAPT (0.71) | MAPTALDH1A1LMNASIRT6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3725771-B1 | ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF | UNIV SHANGHAI TECHNOLOGY (CN) | 2026-02-04 | — | — | EP | disclosed |
| US-12390532-B2 | ALK protein regulator and anti-tumor application thereof | SHANGHAITECH UNIVERSITY (CN) | 2025-08-19 | — | — | US | disclosed |
| US-20250136576-A1 | Heterocyclic Compounds and Uses Thereof | ACEA Therapeutics, Inc. (US) | 2025-05-01 | — | — | US | disclosed |
| US-20250064837-A1 | TARGET PROTEIN DEGRADATION COMPOUNDS, THEIR ANTI-TUMOR USE, THEIR INTERMEDIATES AND USE OF INTERMEDIATES | SHANGHAITECH UNIVERSITY (CN) | 2025-02-27 | — | — | US | disclosed |
| US-12226424-B2 | Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates | SHANGHAITECH UNIVERSITY (CN) | 2025-02-18 | — | — | US | disclosed |
| WO-2024141052-A1 | ESTROGEN-RECEPTOR MODULATOR AND USE THEREOF | 江苏威凯尔医药科技有限公司 | 2024-07-04 | — | — | WO | disclosed |
| CN-118159533-A | Heterocyclic compounds and their use | 艾森医药有限公司 | 2024-06-07 | — | — | CN | disclosed |
| EP-4370212-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA Therapeutics, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2024059525-A2 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANAPLASTIC LYMPHOMA KINASE AND ROS1 KINASE | ENDOTARGET, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20230322723-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | J2H BIOTECH INC. (KR) | 2023-10-12 | — | — | US | disclosed |
| EP-2188292-A1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D]PYRIMIDIN-4-YL) AMINO]BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2010-05-26 | — | — | EP | disclosed |
| WO-2010045451-A1 | PYRROLOPYRIMIDINE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010045451-A1 | PYRROLOPYRIMIDINE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-04-22 | — | — | WO | disclosed |
| EP-2162454-A1 | IMIDAZOPYRIDINE KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2009020990-A1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) AMINO] BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | SMITHKLINE BEECHAM CORPORATION (US) | 2009-02-12 | — | — | WO | disclosed |
| WO-2009020990-A1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) AMINO] BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | SMITHKLINE BEECHAM CORPORATION (US) | 2009-02-12 | — | — | WO | disclosed |
| WO-2008150799-A1 | IMIDAZOPYRIDINE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | ABL1, MAP3K19, MAP3K5 | MAPT 2367/4885ALDH1A1 3410/4885LMNA 2828/4885 |
| US-20230322723-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | EGFR, KRAS, ERBB2 | MAPT 3977/4885ALDH1A1 2871/4885LMNA 4456/4885 |
| US-12390532-B2 | ALK protein regulator and anti-tumor application thereof | ALK, MYC, ALKBH3 | MAPT 4564/4885ALDH1A1 1743/4885LMNA 3426/4885 |
| US-20250064837-A1 | TARGET PROTEIN DEGRADATION COMPOUNDS, THEIR ANTI-TUMOR USE, THEIR INTERMEDIATES AND USE OF INTERMEDIATES | UFM1, SUMO1, SUMO2 | MAPT 2078/4885ALDH1A1 3063/4885LMNA 1077/4885 |
| US-12226424-B2 | Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates | UFM1, SUMO1, SUMO2 | MAPT 2308/4885ALDH1A1 3078/4885LMNA 1132/4885 |
| US-20250136576-A1 | Heterocyclic Compounds and Uses Thereof | CHEK2, CDK2, CDK1 | MAPT 3541/4885ALDH1A1 1877/4885LMNA 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.